|
Market Closed -
Other stock markets
|
After hours 13:48:30 | |||
| 271.00 EUR | +2.50% |
|
274.05 | +1.13% |
| 06-05 | Glenmark Pharmaceuticals Launches Generic Seizure Drug in US | MT |
| 06-04 | UCB and Biogen Inc. Demonstrate Clinical Profile of Dapirolizumab Pegol in Systemic Lupus Erythematosus At EULAR 2026 | CI |
Main competitors
| P/E (N) | Price to Book (N) | PEG (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 28.52x | 4.25x | 2.19x | 5.78x | 16.7x | 21.32x | 0.55% | 58.15B | ||
| 15.58x | 1.81x | -2.26x | 3.36x | 9.06x | 9.91x | 0.65% | 61.21B | ||
| 32.09x | 6.47x | 0.62x | 10.84x | 20.46x | 24.22x | -.--% | 39.54B | ||
| -46.6x | 2.12x | 0.37x | 2.86x | 8.43x | 9.83x | 3.94% | 35.08B | ||
| 31.36x | 1.44x | -1.06x | 3.42x | 10.31x | 12.13x | -.--% | 28.68B | ||
| 17.06x | 3.13x | -4.74x | 2.86x | 8.84x | 8.64x | -.--% | 21.06B | ||
| -5.32x | 3.13x | -0.28x | 7.01x | -4.29x | -4.07x | -.--% | 18.25B | ||
| 47.8x | 4.76x | 0.26x | 5.06x | 36.34x | 33.11x | -.--% | 16.49B | ||
| 24.35x | 3.41x | 0.02x | 5.04x | 13.6x | 18.93x | -.--% | 15.87B | ||
| -30.98x | -5.38x | 0.73x | 14.62x | -44.25x | -46x | -.--% | 13.2B | ||
| -127.4x | 13047.67x | 2.68x | 12.75x | -112.98x | -127.48x | -.--% | 12.68B | ||
| 57.63x | 23.63x | 0.54x | 36.03x | 50.61x | 52.1x | 0.16% | 11.1B | ||
| 15.95x | - | 0.17x | 3.43x | 12.57x | 15.07x | -.--% | 10.86B | ||
| 40.08x | - | 2.87x | - | - | - | -.--% | 9.21B | ||
| 11.79x | 1.03x | 0.41x | 1.8x | 7.28x | 9.69x | 2.85% | 6.28B | ||
| -117.78x | - | 7.8x | - | - | - | -.--% | 5.79B | ||
| 12.97x | 1.2x | -0.19x | 2.22x | 5.74x | 6.9x | 1.72% | 5.26B | ||
| 53.27x | 3.77x | -0.68x | - | - | - | - | 5.05B | ||
| 24.16x | - | 1.19x | 6.39x | 16.96x | 20.25x | 0.43% | 4.93B | ||
| Average | 4.45x | 873.50x | 0.56x | 7.72x | 3.46x | 4.03x | 0.57% | 19.93B | |
| Weighted average by Cap. | 9.48x | 478.89x | 0.06x | 6.60x | 7.50x | 8.83x | 0.65% |
- Stock Market
- Stocks
- UCB Stock
- Sector UCB
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
















